Stephen Saad, Group Chief Executive, Aspen
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Address: Suite 2 Building 4 Ruimsig Office Estate, Hole in One Avenue, Ruimsig, 1724 Roodepoort, Gauteng, South Africa
Tel: +27-11-9582168
Web: http://www.tevapharm.com/Pages/default.aspx
Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence.
Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 47,000 employees worldwide.
Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence.
Teva specializes in development, production and marketing of a wide range of generic and branded products, as well as active pharmaceutical ingredients (API).
For over a century, Teva has maintained a distinct competitive edge through:
High quality offerings
Focus on customers and patients
Balanced product portfolio (both generic and innovative)
Integration of pharmaceutical and API activities
Combination of global operations with local customer responsiveness
Established international presence through a tailored network of worldwide subsidiaries
Teva aims to be the first to introduce the highest quality standards and the most competitive prices.
Teva’s branded products make a significant difference in people’s lives. We leverage our large-scale operations, scientific resources and global leadership to develop and produce drugs that are tailored to address patients’ needs.
Only the highest quality standards are implemented to ensure our customers’ wellbeing. As our branded business expands, we continue to explore new areas and exciting platforms, in pursuit of new products that can enhance your quality of life.
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
See our Cookie Privacy Policy Here
